YR0123
Human CD79B Monoclonal Antibody
Size
£355.00
- SKU:
- YR0123
- Additional Names:
- AGM6|B29|IGB|Igbeta
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Human CD79B
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- P40259
- Synonyms:
- AGM6;B-cell antigen receptor complex-associated protein beta chain;B-cell-specific glycoprotein B29;B29;CD79b antigen (immunoglobulin-associated beta);CD79b molecule, immunoglobulin-associated beta;Ig-beta;IGB;immunoglobulin-associated B29 protein
- Extra Details:
- Polatuzumab is a humanized IgG1-kappa monoclonal antibody against the human CD79B protein, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma (DLBCL) after at least two other cancer treatments did not work or have stopped working. It is given in combination with bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan). Polatuzumab vedotin works by attaching to CD79b and releasing a toxic substance that kills the cancer cells. Polatuzumab biosimilar uses the same protein sequences as the therapeutic antibody polatuzumab.
- Shipping Conditions:
- Blue Ice